These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 39309013)

  • 21. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
    Pan Y; Wang Y; Zheng Y; Chen J; Li J
    Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.
    Sakaeda T; Kadoyama K; Minami K; Okuno Y
    Int J Med Sci; 2014; 11(5):461-5. PubMed ID: 24688309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
    Li Y; Sun S; Wu H; Zhao L; Peng W
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):71. PubMed ID: 39334280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.
    Yu M; Zhou L; Cao M; Ji C; Zheng Y
    Front Immunol; 2024; 15():1397692. PubMed ID: 39234238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Rong L; Xie M; Jiang M; Qiu H; Kong L
    Br J Clin Pharmacol; 2024 Aug; 90(8):1816-1826. PubMed ID: 36702463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS).
    Shi FE; Yu Z; Sun C; Gao P; Zhang H; Zhu J
    Expert Opin Drug Saf; 2024 Feb; 23(2):221-229. PubMed ID: 37554093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system.
    Wen H; Lu C; Zhang M; Qi X
    Expert Opin Drug Saf; 2023; 22(11):1133-1142. PubMed ID: 37578751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).
    Tang H; Xu J; Zhang X; Chen C; Song G; Ma R; Zhao J; Zhao Q
    Front Pharmacol; 2024; 15():1463560. PubMed ID: 39372199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database.
    Zhu J; Hu M; Liang Y; Zhong M; Chen Z; Wang Z; Yang Y; Luo Z; Zeng W; Li J; Du Y; Liu Y; Yang C
    Heliyon; 2024 Jul; 10(14):e34837. PubMed ID: 39149028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database.
    Jiang Y; Lu R; Zhou Q; Shen Y; Zhu H
    Sci Rep; 2024 Apr; 14(1):7659. PubMed ID: 38561511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system.
    Wang Y; Liu X
    Front Pharmacol; 2024; 15():1392263. PubMed ID: 39193332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system.
    Wei W; Huang L; Bai Y; Chang E; Liu J
    Front Pharmacol; 2024; 15():1391003. PubMed ID: 39050747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
    ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mining of adverse event signals associated with inclisiran: a post-marketing analysis based on FAERS.
    Shi X; Qiao Y; Yang Y; Wang N; Zhang Y; Shi S; Shen G; Jia X
    Expert Opin Drug Saf; 2024 Sep; ():1-6. PubMed ID: 39323041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system.
    Zhao J; Tao Y
    Front Pharmacol; 2024; 15():1393940. PubMed ID: 39185318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety assessment of basiliximab using real-world adverse event data from the FDA Adverse Event Reporting System Database: A retrospective observational study.
    Chen S; Ma X; Zhang J
    Medicine (Baltimore); 2024 Sep; 103(36):e39537. PubMed ID: 39252278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database.
    Yuan J; Lu H; Zuo X; Yin L; Pu Y; Zhang J
    Pharmacoepidemiol Drug Saf; 2024 Oct; 33(10):e70030. PubMed ID: 39385705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.
    Chen M; Huang Y; Jiang S; Ke C
    Lung Cancer; 2024 Oct; 196():107966. PubMed ID: 39342769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.